28 trends tracked about this subject — the full history, oldest to newest below.
EU medicines panel recommends AstraZeneca's baxdrostat for uncontrolled hypertension, while new research suggests a potential cure for hormone-driven high blood pressure.
AstraZeneca has acquired St. Louis-based biotech Omniose to add its proprietary bioconjugation platform to the company's infectious disease vaccine pipeline.
A small study found that extended treatment with the aldosterone synthase inhibitor baxdrostat led to sustained blood pressure reduction for up to two years after patients stopped taking the drug.
AstraZeneca reportedly made a $10 billion acquisition offer for obesity drugmaker Rhythm Pharmaceuticals.
AstraZeneca unveils a $1.5 billion savings drive, pledges no layoffs and sees profits surge, sparking a bullish CEO outlook and a share‑price rally.
AstraZeneca is showcasing a new portfolio of targeted cancer therapies, featuring a stomach cancer drug that significantly extended patient survival times.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
AstraZeneca asserts independence for post-2030 growth while investing over $1 billion in a new robotics-driven R&D hub in Cambridge, Massachusetts.
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
AstraZeneca's breast cancer pill Etcamah missed its primary goal in a late-stage trial, adding to oral SERD failures.
AstraZeneca reports positive Phase III trial results for tozorakimab, a drug targeting COPD exacerbations.
AstraZeneca and Sanofi detail new respiratory clinical data at the #ERS26 conference.
AstraZeneca reports significant Phase III trial wins for Tozorakimab, a COPD drug showing broad benefits for current and former smokers.
A failed clinical trial by AstraZeneca and Ionis for eplontersen raises critical questions about the efficacy of silencer drugs in treating heart disease.
AstraZeneca ends a Phase 3 lung cancer drug trial for volrustomig after a formal review determines success is unlikely.
Analysts express perplexity as reports indicate active merger talks between Bristol-Myers Squibb and AstraZeneca.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
AstraZeneca investors are resisting proposed acquisition talks with Bristol Myers valued at $400 billion.
AstraZeneca shares have declined following reports of potential $400 billion merger talks with Bristol Myers Squibb.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
GSK is launching a $2.5 billion cost-saving initiative to accelerate its late-stage drug pipeline and relocate its research headquarters.
AstraZeneca’s earnings beat lifts its stock as oncology sales buoy growth and offset a rare drug miss.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
AstraZeneca shares dropped six percent following a heart drug trial setback that simultaneously boosted rival stocks.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.